Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 11/20 | 0.51 |
| ▸ | FGFR4 | P22455 | 8/20 | 0.51 |
| ▸ | KDR | P35968 | 4/20 | 0.51 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.48 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.48 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 2/20 | 0.39 |
| ▸ | CCND1 | P24385 | 2/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | MARK3 | P27448 | 1/20 | 0.39 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.39 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.39 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.39 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.39 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16050007 | 0.93 | FGFR1 (0.51) | FGFR1FGFR4KDRFGFR2FGFR3 | |
| SCHEMBL16050076 | 0.92 | FGFR1 (0.49) | FGFR1FGFR4KDRFGFR2FGFR3 | |
| SCHEMBL16049996 | 0.83 | FGFR1 (0.49) | FGFR1FGFR4KDRFGFR2FGFR3 | |
| SCHEMBL17469986 | 0.83 | FGFR4 (0.43) | FGFR1FGFR4KDRFGFR2FGFR3 | |
| SCHEMBL17470202 | 0.83 | TNK2 (0.47) | FGFR1FGFR4KDRFGFR3TNK2 | |
| SCHEMBL16070359 | 0.82 | FGFR1 (0.49) | FGFR1FGFR4KDRBRD4ALK | |
| SCHEMBL17470095 | 0.82 | FGFR1 (0.54) | FGFR1FGFR4KDRFGFR2FGFR3 | |
| Fanregratinib SCHEMBL23258768 | 0.82 | FGFR1 (0.46) | FGFR1FGFR4KDRFGFR2FGFR3 | |
| Fanregratinib SCHEMBL16052686 | 0.82 | FGFR1 (0.46) | FGFR1FGFR4KDRFGFR2FGFR3 | |
| SCHEMBL17470066 | 0.81 | FGFR4 (0.43) | FGFR1FGFR4KDRFGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970120-B1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | HUTCHISON MEDIPHARMA LTD (CN) | 2018-09-12 | — | — | EP | disclosed |
| US-9701680-B2 | Pyrimidine and pyridine compounds and their usage | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-07-11 | — | — | US | disclosed |
| US-9701680-B2 | Pyrimidine and pyridine compounds and their usage | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-07-11 | — | — | US | disclosed |
| US-9701680-B2 | Pyrimidine and pyridine compounds and their usage | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-07-11 | — | — | US | disclosed |
| US-20160052926-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND USAGE THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-02-25 | — | — | US | disclosed |
| US-20160052926-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND USAGE THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-02-25 | — | — | US | disclosed |
| US-20160052926-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND USAGE THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-02-25 | — | — | US | disclosed |
| US-20160024021-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-01-28 | — | — | US | disclosed |
| US-20160024021-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-01-28 | — | — | US | disclosed |
| EP-2970120-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | Hutchison Medipharma Limited (CN) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014139465-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014139145-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND USAGE THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052926-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND USAGE THEREOF | FGFR3, FGFR1, FGFR4 | FGFR1 2/4885FGFR4 3/4885KDR 66/4885 |
| US-20160024021-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | FGFR3, FGFR1, FGFR4 | FGFR1 2/4885FGFR4 3/4885KDR 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.